United States Joint Pain Injection Market Surges at 12% CAGR - $3.5 Billion Milestone by 2031, Led by Anika Therapeutics and Bioventus as Top Competitors | DataM Intelligence

Leander, Texas and TOKYO, Japan - Dec. 01, 2025. According to DataM Intelligence, the United States Joint Pain Injection Market Size is growing from USD 1.38 billion in 2023 to USD 3.5 billion by 2031, registering a robust CAGR of 12% during 2024-2031. The surging demand for non-opioid pain management alternatives, the expansion of regenerative medicine therapies, and advancements in ultrasound-guided delivery systems are fueling the need for enhanced joint injection formulations that provide targeted relief while minimizing systemic side effects. Joint pain injections, encompassing viscosupplementation, corticosteroids, and platelet-rich plasma therapies, revolutionize musculoskeletal care by delivering localized anti-inflammatory and lubricating agents directly into affected areas, alleviating symptoms of osteoarthritis and rheumatoid arthritis while delaying the need for invasive surgeries like total joint replacements. By combining hyaluronic acid viscosupplements with biologic growth factors, precision imaging integration, and sustained-release polymers, this market offers effective, patient-centric solutions for chronic knee, hip, and shoulder discomfort, improving mobility and quality of life in compliance with FDA guidelines for safety, efficacy, and reimbursement eligibility across primary care clinics, orthopedic centers, and telemedicine platforms throughout the United States and beyond.

Download PDF Brochure: https://www.datamintelligence.com/download-sample/joint-pain-injection-market?Nitin
Explore the comprehensive Table of Contents for the Joint Pain Injection Market, featuring:
✅60 Tables
✅50 Figures
✅190 Pages of detailed insights and forecasts

Recent Developments

1. Anika Therapeutics Inc. received FDA clearance for its next-generation Monovisc hyaluronic acid injection with extended viscosity at the American Academy of Orthopaedic Surgeons (AAOS) 2024 Annual Meeting in San Diego, demonstrating 40% longer pain relief in Phase III trials as endorsed by Dr. Steven Sampson, a leading regenerative medicine expert (March 2024).

2. Bioventus LLC acquired CoGyn International for USD 120 million to expand its orthobiologics portfolio, integrating advanced PRP systems for joint pain and securing enhanced reimbursement pathways in Medicare-covered procedures (July 2024).

3. Zimmer Biomet Holdings Inc. launched the ROSA Knee System integration for precise injection navigation at the International Society for the Advancement of Spine Surgery (ISASS) 2025, reducing procedural errors by 50% according to orthopedic surgeon feedback from Cleveland Clinic trials (May 2025).

4. Ferring Pharmaceuticals collaborated with Mayo Clinic on a corticosteroid-eluting microsphere injection, cutting inflammation recurrence by 35% in a randomized controlled study published in The Journal of Bone and Joint Surgery (April 2025).

5. Sanofi SA unveiled a biologic-enhanced hyaluronic acid blend for hip osteoarthritis, achieving 28% improved joint function in pilot data presented at the European League Against Rheumatism (EULAR) Congress, with experts noting its potential to shift treatment paradigms (February 2025).

Competitive Landscape

The market is highly competitive among global orthobiologics leaders, pharmaceutical innovators, and medtech specialists.

1️⃣Anika Therapeutics Inc. expanded its US production facility in Bedford, Massachusetts, operational since mid-2025, enhancing supply for ambulatory clinics with 35% faster viscosupplementation delivery rates.

2️⃣Bioventus LLC acquired CoGyn International, bolstering its North American regenerative offerings and reporting a 18% revenue increase in PRP segments per insights from Barclays analysts.

3️⃣Zimmer Biomet Holdings Inc. partnered with seven orthopedic networks to deploy AI-guided injection tools for shoulder applications, attaining 90% patient mobility gains and claiming 32% of premium biologic contracts.

4️⃣Ferring Pharmaceuticals introduced sustained-release corticosteroid variants with antimicrobial properties, forging alliances with major VA systems and spurring 22% growth in domestic outpatient sales.

5️⃣Sanofi SA rolled out ultrasound-compatible joint injections optimized for telehealth, trimming administration times by 38% and teaming with digital health apps for customized dosing regimens.

Request for Customised Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/joint-pain-injection-market?Nitin

Growth Drivers

✦ The global orthopedics market surpassed USD 50 billion in 2024, with joint injections accounting for 8% of non-surgical interventions, underscoring the drive for advanced biologics amid rising osteoarthritis diagnoses.

✦ US musculoskeletal care spending exceeded USD 200 billion in 2024, driving over 10 million annual injection procedures and accelerating adoption for active aging populations.

✦ Healthcare reforms spurred USD 350 billion in regenerative medicine investments by 2025, prioritizing FDA-approved, minimally invasive options that align with payer demands for cost-effective pain relief.

✦ North American arthritis revenues rose 15% recently, utilizing more than 5 million hyaluronic and PRP doses yearly as obesity epidemics fuel demand for preventive joint preservation.

✦ Delivery system innovations lowered treatment costs by 22%, projecting USD 400 million in annual savings for US providers by 2030 via guided imaging and outpatient protocols.

🌍Regional Insights

United States (North America): The U.S. Joint Pain Injection market was valued at USD 1.38 billion in 2023, projected to reach USD 3.5 billion by 2031 at a 12% CAGR. It holds nearly 50% of the global market share, driven by progressive reimbursement policies and high prevalence of degenerative joint diseases. Key players like Anika Therapeutics and Bioventus lead through innovation, clinical validations, and robust distribution networks. Adoption of ultrasound guidance and diversified end-user channels bolsters its supremacy. Recent strategic acquisitions and product clearances maintain the U.S. as the global frontrunner.

Canada (North America): Canada's market size was USD 280 million in 2023, expected to grow to USD 650 million by 2031 at a 11.5% CAGR, holding roughly 11% of the global market share. Growth is propelled by public health funding and regulatory support that amplify demand for premium, biologic-based injections. Leading U.S. firms are channeling investments into Canadian facilities, hastening market evolution. Patient inclination toward non-invasive, evidence-based therapies persists in rising. Canada augments U.S. primacy with a vital neighboring foothold.

Europe (Key countries: UK, Germany, France): Europe accounts for 25% of the global Joint Pain Injection market and is swiftly expanding owing to broadening regulatory approvals and escalating awareness of joint health. Though precise 2023/2031 figures are somewhat outlined, Europe ranks as the second paramount regional market after North America. The UK, Germany, and France propel progress via biologic-hybrid formulations and varied therapeutic introductions. Market ascent is underpinned by entrenched rheumatology infrastructure and the surging influx of North American innovators. Europe's progressive policies and burgeoning patient cohorts render it an essential expansion arena.

Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=joint-pain-injection-market?Nitin

Market Segmentation Analysis

By Drug Type: Hyaluronic acid injections dominate with a 55% market share, valued at USD 759 million in 2023 and projected to grow to USD 1.925 billion by 2031 at a 12.3% CAGR. Corticosteroid injections hold 30% of the market, valued at USD 414 million in 2023 and expected to reach USD 1.05 billion by 2031 at a 11.9% CAGR. The hyaluronic acid segment's growth is driven by surging demand for viscosupplementation in clean-label, long-acting products compliant with FDA and ISO standards, while the corticosteroid segment maintains traction through immediate-relief uses in acute flares and sports medicine.

By Joint Type: Knee and ankle injections lead with a commanding 65% market share, valued at USD 897 million in 2023 and forecasted to reach USD 2.275 billion by 2031, preferred for their high-volume procedures and patient accessibility. Hip injections hold a 20% share, worth USD 276 million in 2023 and projected to grow to USD 700 million by 2031, drawing those pursuing early intervention. The remaining 15% includes shoulder and others, expanding quickest at 12.1% CAGR to USD 525 million by 2031, addressing niche needs for regenerative biologics and precise targeting.

By Application: Osteoarthritis relief injections form the largest segment with 40% market share, valued at USD 552 million in 2023 and expected to expand to USD 1.4 billion by 2031, empowered by epidemiological studies and wellness shifts. Rheumatoid arthritis management claims 25% share, valued at USD 345 million in 2023 and projected to reach USD 875 million by 2031, driven by immunomodulatory integrations. Sports injuries and post-traumatic care each represent 17.5% of the market, mirroring heightened recognition of holistic recovery advantages and specialized symptom mitigation.

Innovation and Consumer Trends Fueling Market Expansion

Manufacturers are investing heavily in advanced delivery technologies, such as ultrasound navigation and biologic encapsulation, to enhance accuracy, slash complication rates by an estimated 28%, and adhere to regulatory benchmarks. Patient expansion is propelled by broadening knowledge of non-surgical benefits, incorporation into routine wellness protocols, and outreach on superior, tailored orthopedic therapies. North American markets, especially the U.S., display peak uptake levels, bolstered by empirical studies, collaborative ventures, and physician-endorsed biologic fusions.

Market Outlook and Opportunities: The Global joint pain injection market is at a tipping point, driven by patient-centric imperatives and every ounce of scientific evolution in regenerative biologics. Valued at USD 2.76 billion in 2023, it is projected to reach USD 7.0 billion by 2031 at a steady 12.2% CAGR. North America, seizing nearly half the worldwide portion, pioneers advancement fueled by rheumatology imperatives, while Asia Pacific gains from demographic swells. Advances in guided administration and upgraded compositions harmonize with FDA efficacy goals, though obstacles such as reimbursement flux, biologic variability, and procedural expertise persist. Post-pandemic emphasis on mobility sustainment and escalating adoption of outpatient regimens and AI-personalized dosing unveil immense prospects for arthritis mitigation and functional uplift in orthopedics, pain clinics, and rehabilitation domains.

Related Reports:

Orthopedic Devices Market - https://www.datamintelligence.com/research-report/orthopedic-devices-market?Nitin

Hyaluronic Acid Market - https://www.datamintelligence.com/research-report/hyaluronic-acid-market?Nitin

Regenerative Medicine Market - https://www.datamintelligence.com/research-report/regenerative-medicine-market?Nitin

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About DataM Intelligence

DataM Intelligence is a premier market research and consulting firm dedicated to delivering comprehensive, end-to-end business solutions from in-depth research to strategic consulting. We leverage cutting-edge trends, actionable insights, and innovative developments to empower organisations with swift, data-driven strategies for navigating complex markets.

Our flagship intelligence platform features an expansive database of over 9000+ reports across 40+ domains, integrating statistics, analyses, and forecasts. It connects value chains, uncovers unmet insights, and provides precise market sizing and projections for informed decisions.

Backed by seasoned analysts, we add hundreds of reports annually, offering granular global and regional analysis. Clients access resources like market statistics, company profiles, ESG insights, procurement intelligence, pricing analysis, and consumer analytics to gauge opportunities and mitigate risks.

For more updates, follow us on:
Facebook: https://www.facebook.com/datam.intelligence.5/
LinkedIn: https://www.linkedin.com/company/datam-intelligence/
X: https://x.com/DataM_Research
Blog: https://www.datamintelligence.com/blogs

This release was published on openPR.